Fibrotic liver disease/NASH/inflammatory bowel disease drug (Engitix/Takeda)

N/A

Report date: 2025/01/26 16:16:10
NME

Base Information

Drug NameFibrotic liver disease/NASH/inflammatory bowel disease drug (Engitix/Takeda)
Drug Alias NameFibrotic liver disease/NASH drug (Engitix/Takeda)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsLiver CirrhosisMetabolic Dysfunction-Associated Steatotic Liver DiseaseCrohn Disease +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited KingdomJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEngitix Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTakeda Pharmaceutical Co LtdEngitix Ltd
Inactive CompaniesN/A
Active IndicationsLiver CirrhosisMetabolic Dysfunction-Associated Steatotic Liver DiseaseCrohn Disease +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A